Targeting a specific type of kidney cancer caused by gene fusions
Official title: Therapeutic targeting for translocation renal cell carcinoma
Funded at State University of New York at Buffalo · NIH-10944705 · Data updated 2026-11-12
This study is looking for new treatments for a rare and tough type of kidney cancer called translocation renal cell carcinoma (tRCC) by finding small molecules that can block the harmful interactions between certain proteins that help the cancer grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $368,288 |
| NIH project number | 1R01CA292851-01 |
| Project ID | NIH-10944705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with translocation renal cell carcinoma, particularly those who have not responded to existing treatments.
✕Less likely to help
Patients with other types of kidney cancer or those without the specific gene fusions associated with tRCC may not benefit from this research.
What this research studies
This research focuses on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer that often goes misdiagnosed. The study aims to identify small molecules that can disrupt the interactions between specific proteins involved in the cancer's progression. By utilizing advanced imaging techniques, researchers will explore how these proteins interact and how they can be targeted to inhibit cancer cell growth. The goal is to develop effective therapies for patients suffering from this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for patients with translocation renal cell carcinoma.
How similar studies have gone: While research on targeted therapies for tRCC is limited, preliminary studies have shown promise in targeting the protein interactions involved in this cancer type.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Pili, Roberto — State University of New York at Buffalo
- Study coordinator: Pili, Roberto
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.